Browse by author
Lookup NU author(s): Dr Paul Sinclair, Dr Ruth Cranston, Prahlad Raninga, Joanna Cheng, Rebecca Hanna, Zoe Hawking, Dr Steven HairORCiD, Sarra Ryan, Dr Amir EnshaeiORCiD, Dr Vikki Rand, Dr Helen Blair, Professor Anthony MoormanORCiD, Professor Olaf Heidenreich, Professor Christine Harrison FRCPath FMedSci
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2023, The Author(s).A common problem in the study of human malignancy is the elucidation of cancer driver mechanisms associated with recurrent deletion of regions containing multiple genes. Taking B-cell acute lymphoblastic leukaemia (B-ALL) and large deletions of 6q [del(6q)] as a model, we integrated analysis of functional cDNA clone tracking assays with patient genomic and transcriptomic data, to identify the transcription factors FOXO3 and PRDM1 as candidate tumour suppressor genes (TSG). Analysis of cell cycle and transcriptomic changes following overexpression of FOXO3 or PRDM1 indicated that they co-operate to promote cell cycle exit at the pre-B cell stage. FOXO1 abnormalities are absent in B-ALL, but like FOXO3, FOXO1 expression suppressed growth of TCF3::PBX1 and ETV6::RUNX1 B-ALL in-vitro. While both FOXOs induced PRDM1 and other genes contributing to late pre-B cell development, FOXO1 alone induced the key transcription factor, IRF4, and chemokine, CXCR4. CRISPR-Cas9 screening identified FOXO3 as a TSG, while FOXO1 emerged as essential for B-ALL growth. We relate this FOXO3-specific leukaemia-protective role to suppression of glycolysis based on integrated analysis of CRISPR-data and gene sets induced or suppressed by FOXO1 and FOXO3. Pan-FOXO agonist Selinexor induced the glycolysis inhibitor TXNIP and suppressed B-ALL growth at low dose (ID50 < 50 nM). [Figure not available: see fulltext.].
Author(s): Sinclair PB, Cranston RE, Raninga P, Cheng J, Hanna R, Hawking Z, Hair S, Ryan SL, Enshaei A, Nakjang S, Rand V, Blair HJ, Moorman AV, Heidenreich O, Harrison CJ
Publication type: Article
Publication status: Published
Journal: Leukemia
Year: 2023
Volume: 37
Pages: 636–649
Online publication date: 20/01/2023
Acceptance date: 10/01/2023
Date deposited: 07/02/2023
ISSN (print): 0887-6924
ISSN (electronic): 1476-5551
Publisher: Springer Nature
URL: https://doi.org/10.1038/s41375-023-01816-0
DOI: 10.1038/s41375-023-01816-0
PubMed id: 36670235
Altmetrics provided by Altmetric
